What is the usual medication review process before starting an SSRI?

Before starting an SSRI, clinicians complete a person-centred medication review that assesses symptom severity, comorbidities, and drug interactions, discusses non-pharmacological options, shared expectations, adverse effects, and stopping plans, then schedules early follow-up for tolerance and response, usually within two weeks or one week if the person is under 25 or at suicide risk.

Medication Review Before Starting an SSRI

Published: 2026-09-30

SSRI medication review depression

Quick answer: Assess severity, comorbidities, and interactions; counsel on benefits, harms, and stopping; then plan early follow-up within one to two weeks.

Starting an SSRI is not a single prescribing decision. Clinical guidance frames it as a structured, person-centred medication review: confirm that medicine is appropriate, check safety against existing conditions and drugs, agree goals with the patient, and set a clear early review plan before the first dose.

Why Review Matters Before the First Dose

Antidepressants can help moderate to severe depression and several anxiety disorders, especially when combined with psychological care. For less severe depression they are often not first-line. Guides also note that depressive symptoms can resolve spontaneously for many people within about 12 weeks, so rushed initiation adds avoidable exposure to adverse effects and later withdrawal problems.

A pre-start review reduces that risk by separating "who needs an SSRI now" from "who needs stepped care, watchful waiting, or non-drug support first."

Step 1: Assess Severity and Therapeutic Objectives

Begin with a holistic assessment of symptom severity and what matters to the patient. Validated scales such as PHQ-9 support clinical judgment. Thresholds used in NICE-aligned guidance treat PHQ-9 scores under 16 as less severe depression and scores of 16 or more as more severe.

Document the indication clearly, distinguish depressive illness from other uses of antidepressants (for example neuropathic pain), and define therapeutic objectives: symptom control, functional recovery, relapse prevention, or a time-limited trial.

Step 2: Use Stepped Care Before Medicine When Appropriate

Do not routinely offer antidepressant medication as first-line treatment for less severe depression unless that is the person's preference. Prefer self-help, physical activity, and psychological interventions where guidance supports them.

A medicine trial may still be reasonable for people with a history of moderate or severe depression, long-standing sub-threshold symptoms (typically at least two years), or mild symptoms that persist after other interventions.

For moderate to severe depression, antidepressants are more likely to help, and combining medicine with psychological therapy tends to improve outcomes and continuity of care.

Step 3: Review Comorbidities and Current Medicines

As part of the biopsychosocial assessment, review comorbidities and the potential for interactions with other medicines and diseases, including QTc prolongation concerns with some SSRIs.

Check existing antidepressants even at low dose (for example amitriptyline for neuropathic pain) before adding another agent for depression. Note combinations that raise harm risk, such as an SSRI with antiplatelets, NSAIDs, DOACs, or warfarin without gastroprotection in older adults, and avoid stacking medicines with overlapping toxicity when possible.

Step 4: Shared Decision on Benefits, Limits, and Stopping

Before starting treatment, discuss with the individual:

expectations of both patient and prescriber
stepped care and watchful waiting where relevant
effective non-pharmacological options
drug effects and limitations, including SSRI flat dose-response for depression (standard doses such as 20 mg daily of citalopram, fluoxetine, or paroxetine, or 50 mg daily of sertraline, often provide the full antidepressant effect)
short- and long-term adverse effects such as nausea, agitation, sedation, and sexual dysfunction
how and when treatment may be reduced and stopped later to limit drug-related harm
discontinuation or withdrawal effects if doses are missed or stopped abruptly

Provide written information on the condition, the medicine, and stopping plans. Agree clear therapeutic goals and a likely response window (some benefit may appear within one to two weeks, with fuller assessment over the first weeks of treatment).

Step 5: Choose the Agent and a Therapeutic Starting Plan

SSRIs are generally well tolerated and are often first-line pharmacological options when medicine is indicated, unless history, comorbidities, or preference point elsewhere. Prefer agents with fewer interaction concerns when chronic physical illness is present; some guidance notes higher interaction propensity for fluoxetine, fluvoxamine, and paroxetine.

Titrate promptly to a recognised minimum effective dose rather than lingering on subtherapeutic regimens. For SSRIs used in depression, increasing beyond standard doses often adds adverse effects without clear efficacy gain; switching may be more appropriate than dose escalation if response is poor.

Step 6: Schedule Early Safety and Efficacy Follow-Up

Set the review schedule before the prescription leaves the room. Guidance consistently calls for early contact to check tolerance, concordance, and symptom change:

usually within two weeks after initiation
within one week for people under 25, or when suicide risk is a concern
again as needed, and no later than about four weeks after starting

Monitor suicidal ideation especially in early weeks, and keep a risk management plan active. Use clinical review plus tools such as PHQ-9 when helpful. If there is no response at two to four weeks on a standard SSRI dose, reassess diagnosis and adherence before changing medicine. Partial response at four weeks may call for adding or revisiting non-pharmacological care rather than automatic dose increases.

Step 7: Apply a Structured 7-Steps Medication Review Lens

Scottish quality-prescribing advice maps initiation and ongoing review to a 7-Steps process that clinicians can reuse before and after starting an SSRI:

What matters to the patient, and what are the limits of drug therapy?
Identify essential drug therapy that should not stop without specialist advice.
Ask whether any current medicines are unnecessary (temporary indications completed, higher-than-needed SSRI doses, limited-benefit co-prescribing such as long-term benzodiazepines).
Check whether therapeutic objectives are being achieved or need intensification.
Screen for adverse effects, drug-drug and drug-disease interactions, and overdose risk.
Consider cost-effective options without sacrificing safety or convenience.
Confirm the patient can and will take the plan as intended, then agree and communicate the follow-up plan.

This same structure supports later proactive reviews for people on long-term antidepressants, including those treated for two years or more.

Red Flags Requiring Closer Oversight

Escalate intensity of review or specialist input when you see:

new or rising suicidal ideation, self-harm thoughts, or high suicide risk after starting or increasing dose
age under 25 years at initiation (earlier and more frequent review)
significant drug-disease interaction risk, including QTc concerns (for example citalopram dose limits of 40 mg in adults and 20 mg in older people in primary-care monitoring guidance)
co-prescribing that raises bleeding or toxicity risk in older or frail adults
less severe depression where medicine was started without preference or failed non-drug care
inability to arrange early follow-up within the recommended window

Common Questions

Is an SSRI appropriate for mild depression?

Not routinely. The risk-benefit ratio is poor for mild or less severe depression, so non-pharmacological options come first unless the person prefers medicine or symptoms are persistent after other care.

How soon should patients be reviewed after starting?

Within two weeks for most people, or within one week if younger than 25 or if suicide risk is elevated, then again as needed and no later than about four weeks.

Should the dose be increased if there is little early benefit?

Not automatically. Many SSRIs show a flat dose-response for depression at standard doses. Recheck diagnosis and adherence first; changing antidepressant may be more useful than pushing the dose higher.

What counseling is required about stopping?

Discuss discontinuation effects up front, advise against abrupt stops, and plan a gradual taper when treatment ends. Patients should know common withdrawal symptoms and when to seek help.

Protocol Summary

Confirm diagnosis, severity (clinical review plus scale such as PHQ-9), and patient priorities
Offer stepped care and non-pharmacological options when less severe depression is present
Review comorbidities, bleeding risk, QTc concerns, and all current medicines for interactions
Complete shared decision counseling on benefits, limits, adverse effects, response time, and stopping
Select SSRI (or alternative) based on history, safety, and preference; use a standard effective dose
Document indication, goals, and written patient information
Book early review within 2 weeks (1 week if under 25 or suicide risk) and plan further checks by 4 weeks
Monitor concordance, side effects, mood, and suicidal ideation at each contact
Reassess need for continuation, switch, or deprescribing using the 7-Steps framework over time

How Rovetia Helps

Rovetia keeps the pre-SSRI review trail in one place: prior diagnoses, medication lists, counseling notes, PHQ-9 scores, and scheduled safety follow-ups. Clinicians can pull structured history from uploads and dictation, link appointments to the patient timeline, and use AI chat against the full clinic record when preparing initiation or early review visits, with human verification before any clinical decision.

Sources: Right Decisions guidance on person-centred antidepressant initiation and antidepressant polypharmacy review, and Scottish quality prescribing advice on the 7-Steps medication review for antidepressants.